Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 76 - 100 of 2706 in total
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone...
Approved
Illicit
Investigational
Matched Salts cas: … 124-90-3 …
Matched Products: … OXICUT 5 MG KAPSÜL ,90 KAPSÜL ... OXOPANE 5MG KAPSÜL, 90 KAPSÜL ... OXICUT 10 MG KAPSÜL ,90 KAPSÜL …
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approved
Investigational
Matched Products: … I.N.H 100 MG TABLET, 90 ADET …
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Description: … sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 ... Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 ... L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19
Matched Categories: … Approved Treatments for COVID-19 ... Experimental Unapproved Treatments for COVID-19
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused …
Matched Mixtures name: … Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent …
Matched Categories: … COVID-19 Vaccines …
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Mixtures name: … DOMINGO 5/5/80 MG EFERVESAN TABLET, 90 ADET ... DOMINGO 5/10/80 MG EFERVESAN TABLET, 90 ADET ... EVERON 90/5 MG FILM KAPLI TABLET ,50 TABLET …
Matched Products: … COGITO 20 MG FILM TABLET, 90 ADET ... ANGETİN 20MG FİLM TABLET, 90 TABLET ... FEMTA 20 MG FİLM KAPLI TABLET, 90 ADET …
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 …
Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. It is produced using recombinant DNA technology in CHO cell lines and...
Approved
Matched Description: … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein ... the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19
Matched Categories: … COVID-19 Vaccines …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow...
Approved
Vet approved
Matched Description: … Oxygen is an element displayed by the symbol O, and atomic number 8. …
Matched Products: … Oxygen/Nitrogen 10/90 ... OXIGENO MEDICINAL(90%-96%) …
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Description: … FDA approved on February 8, 2013. …
Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Iupac: … 5,7-diiodoquinolin-8-ol …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more...
Approved
Vet approved
Matched Salts cas: … 5611-51-8
Matched Products: … Volon 8 mg - Tabletten …
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Products: … PIDREX 1MG AĞIZDA DAĞILAN TABLET, TABLET, 90 ADET ... PIDREX 0,5MG AĞIZDA DAĞILAN TABLET, TABLET, 90 ADET ... PIDREX 1,5MG AĞIZDA DAĞILAN TABLET, TABLET, 90 ADET …
Approved
Experimental
Matched Mixtures name: … Se-Natal 19 ... Thrivite 19 ... Se-Natal 19
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Mixtures name: … Ciclopirox 8% / Fluconazole 1% / Terbinafine HCl 1% …
Matched Products: … FLUCAN 150 MG KAPSUL, 8 ADET ... FLUZAMED 150 MG KAPSÜL ,8 KAPSÜL …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 ... October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 ... October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
Approved
Investigational
A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical
Matched Mixtures name: … Numeta G 19 % E Emulsion zur Infusion ... NUMETA PED G 19 % E INFÜZYON IÇIN EMÜLSIYON, 1000 ML ... AMINOSTERIL N-HEPA 8% …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels...
Approved
Investigational
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its...
Approved
Vet approved
Matched Mixtures name: … Theraproxen-90 ... TIYOKSEN 550 MG/8 MG FILM TABLET,10 ADET ... TIYOKSEN 550 MG/8 MG FILM TABLET,14 ADET …
Displaying drugs 76 - 100 of 2706 in total